Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Total Liabilities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Total Liabilities for 4 consecutive years, with $61.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 109.86% to $61.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $61.1 million, a 109.86% increase, with the full-year FY2024 number at $43.2 million, up 59.06% from a year prior.
  • Total Liabilities was $61.1 million for Q3 2025 at Orchestra BioMed Holdings, up from $42.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $61.1 million in Q3 2025 to a low of $5.9 million in Q1 2022.
  • A 4-year average of $31.4 million and a median of $36.4 million in 2023 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 518.43% in 2023; the steepest drop was 36.87% in 2023.
  • Orchestra BioMed Holdings' Total Liabilities stood at $43.0 million in 2022, then tumbled by 36.87% to $27.2 million in 2023, then soared by 59.06% to $43.2 million in 2024, then soared by 41.31% to $61.1 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Total Liabilities are $61.1 million (Q3 2025), $42.5 million (Q2 2025), and $42.2 million (Q1 2025).